Amyloid Leukemia (Therapy)

Interleukin-2 Can Be Safely Administered to Leukemia Patients

Published in Cancer Weekly, November 15th, 1999

Interleukin-2 (IL-2) may be safely administered to amyloid leukemia (AML) patients in their first remission.

D. Skoric and colleagues from the University Children's Hospital, Yugoslavia, employed IL-2 therapy in five pediatric patients entering their first AML remission.

The results from their study were presented at the joint meeting of the International Society of Pediatric Oncology, the American Society for Pediatric Hematology/Oncology, and the 31st Annual Meeting of the International Society of Pediatric Surgical Oncology, held September 13-18, 1999, in Montreal, Canada.

"In 80 percent of patients with AML it is possible to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry